BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 33945380)

  • 1. MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
    Lee M; Jain P; Wang F; Ma PC; Borczuk A; Halmos B
    Expert Opin Ther Targets; 2021 Apr; 25(4):249-268. PubMed ID: 33945380
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
    Fujino T; Suda K; Mitsudomi T
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):229-249. PubMed ID: 32615820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Reungwetwattana T; Liang Y; Zhu V; Ou SI
    Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MET alterations in NSCLC-Current Perspectives and Future Challenges.
    Remon J; Hendriks LEL; Mountzios G; García-Campelo R; Saw SPL; Uprety D; Recondo G; Villacampa G; Reck M
    J Thorac Oncol; 2023 Apr; 18(4):419-435. PubMed ID: 36441095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.
    DaSilva JO; Yang K; Surriga O; Nittoli T; Kunz A; Franklin MC; Delfino FJ; Mao S; Zhao F; Giurleo JT; Kelly MP; Makonnen S; Hickey C; Krueger P; Foster R; Chen Z; Retter MW; Slim R; Young TM; Olson WC; Thurston G; Daly C
    Mol Cancer Ther; 2021 Oct; 20(10):1966-1976. PubMed ID: 34315762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MET alterations in advanced non-small cell lung cancer.
    Chagas GCL; Rangel AR; El Osta B
    Curr Probl Cancer; 2024 Apr; 49():101075. PubMed ID: 38480027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
    Spagnolo CC; Ciappina G; Giovannetti E; Squeri A; Granata B; Lazzari C; Pretelli G; Pasello G; Santarpia M
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capmatinib for the treatment of non-small cell lung cancer.
    Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
    [No Abstract]   [Full Text] [Related]  

  • 9. C-MET inhibitors for advanced non-small cell lung cancer.
    Pasquini G; Giaccone G
    Expert Opin Investig Drugs; 2018 Apr; 27(4):363-375. PubMed ID: 29621416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progress on Mechanism of MET Gene Mutation and Targeted Drugs in Non-small Cell Lung Cancer].
    Han S; Ma X; Fang J
    Zhongguo Fei Ai Za Zhi; 2020 Jul; 23(7):609-614. PubMed ID: 32702795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
    Yin L; Lu Y
    Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):553-559. PubMed ID: 30037377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].
    Baldacci S; Kherrouche Z; Descarpentries C; Wislez M; Dansin E; Furlan A; Tulasne D; Cortot AB
    Rev Mal Respir; 2018 Oct; 35(8):796-812. PubMed ID: 30174236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
    J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
    Vuong HG; Ho ATN; Altibi AMA; Nakazawa T; Katoh R; Kondo T
    Lung Cancer; 2018 Sep; 123():76-82. PubMed ID: 30089599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.
    Lai GGY; Guo R; Drilon A; Shao Weng Tan D
    Cancer Treat Rev; 2022 Nov; 110():102444. PubMed ID: 36108503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 
Skipping Mutation].
    Editorial Office of Chinese Journal of Lung Cancer
    Zhongguo Fei Ai Za Zhi; 2023 Jun; 26(6):416-428. PubMed ID: 37488079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.